Pulmonx Corp(LUNG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LUNG Pulmonx Corp

Post-Mkt 05-27 19:27:11 EDT

1.54

-0.03

-1.91%

盘后1.52

-0.02-1.30%

18:15 EDT

High1.61	Low1.52	Vol330.30K
Open1.58	D1 Closing1.57	Amplitude5.73%
Mkt Cap65.05M	Tradable Cap62.26M	Total Shares42.24M
T/O515.88K	T/O Rate0.82%	Tradable Shares40.43M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LUNG","market":"US","secType":"STK","nameCN":"Pulmonx Corp","latestPrice":1.54,"timestamp":1779912000000,"preClose":1.57,"halted":0,"volume":330303,"hourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.54,"latestTime":"18:15 EDT","volume":2028,"amount":3123.0800484,"timestamp":1779920137576,"change":-0.02,"changeRate":-0.012987,"amplitude":0.012987},"delay":0,"changeRate":-0.019108280254777087,"floatShares":40428900,"shares":42237203,"eps":-1.292368,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"05-27 19:27:11 EDT","open":1.58,"high":1.6099,"low":1.52,"amount":515881.56055020005,"amplitude":0.057261,"askPrice":1.54,"askSize":555,"bidPrice":1.45,"bidSize":10,"shortable":3,"etf":0,"ttmEps":-1.292368,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1779926400000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1601524800000,"exchange":"NASDAQ","adjPreClose":1.57,"preHourTrading":{"tag":"盘前","latestPrice":1.569,"preClose":1.57,"latestTime":"08:44 EDT","volume":62,"amount":97.5240036,"timestamp":1779885859366,"change":-0.001,"changeRate":-0.000637,"amplitude":0.026115},"postHourTrading":{"tag":"盘后","latestPrice":1.52,"preClose":1.54,"latestTime":"18:15 EDT","volume":2028,"amount":3123.0800484,"timestamp":1779920137576,"change":-0.02,"changeRate":-0.012987,"amplitude":0.012987},"volumeRatio":0.631381,"impliedVol":1.2654,"impliedVolPercentile":0.6653},"requestUrl":"/m/hq/s/LUNG/tweets","defaultTab":"tweets","newsList":[{"id":"2633991180","title":"Pulmonx publishes investor presentation on Zephyr valves for severe emphysema treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2633991180","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633991180?lang=en_us&edition=fundamental","pubTime":"2026-05-05 13:52","pubTimestamp":1777960365,"startTime":"0","endTime":"0","summary":"Pulmonx outlined a severe emphysema total addressable market of about USD 12 billion, citing about 1.2 million eligible collateral ventilation-negative patients in major markets.1Q26 revenue totaled USD 20.6 million, including USD 13.3 million in U.S. revenue, USD 7.3 million outside U.S. revenue.Cash, cash equivalents, and marketable securities totaled USD 61.6 million as of 3/31/2026.Pipeline update highlighted AeriSeal as an investigational bronchoscopic foam intended to convert some collateral ventilation-positive patients to enable subsequent Zephyr valve treatment, targeting at least a 20% expansion in addressable market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pulmonx Corporation published the original content used to gen","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260505:nNDL8xvxgt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632695145","title":"Pulmonx Earnings Call: Margin Gains Amid Growth Pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2632695145","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632695145?lang=en_us&edition=fundamental","pubTime":"2026-05-01 08:58","pubTimestamp":1777597131,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation (($LUNG)) has held its Q1 earnings call. Read on for the main highlights of the call. Pulmonx’s latest earnings call struck a c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmonx-earnings-call-margin-gains-amid-growth-pause?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmonx-earnings-call-margin-gains-amid-growth-pause?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LUNG","BK4082","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632652162","title":"Lake Street Remains a Buy on Pulmonx (LUNG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632652162","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632652162?lang=en_us&edition=fundamental","pubTime":"2026-05-01 00:36","pubTimestamp":1777566965,"startTime":"0","endTime":"0","summary":"Lake Street analyst Frank Takkinen reiterated a Buy rating on Pulmonx today and set a price target of $4.00. Takkinen covers the Healthcare sector,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-pulmonx-lung-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/lake-street-remains-a-buy-on-pulmonx-lung-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","XLV","LUNG","XBI","BK4588","LABU","BK4581","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631632348","title":"Pulmonx Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2631632348","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631632348?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:18","pubTimestamp":1777551480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUNG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 30, 2026 08:18 ET (12:18 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631163678","title":"Analysts Conflicted on These Healthcare Names: Teladoc (TDOC), Madrigal Pharmaceuticals (MDGL) and Pulmonx (LUNG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631163678","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631163678?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:20","pubTimestamp":1777548049,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC), Madrigal Pharmaceuticals (MDGL) and Pulmonx (LUNG...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-teladoc-tdoc-madrigal-pharmaceuticals-mdgl-and-pulmonx-lung-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-teladoc-tdoc-madrigal-pharmaceuticals-mdgl-and-pulmonx-lung-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","BK4585","BK4534","BK4567","BK4581","LU1861558580.USD","LABU","BK4139","BK4548","LUNG","BK4082","BK4588","LU0029874061.USD","XBI","TDOC","BK4167","BK4137","LU0128526141.USD","HCSG","MDGL","LU1861559042.SGD","BK4504","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631248875","title":"Pulmonx Corp reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2631248875","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631248875?lang=en_us&edition=fundamental","pubTime":"2026-04-30 05:01","pubTimestamp":1777496494,"startTime":"0","endTime":"0","summary":"Pulmonx Corp reports results for the quarter ended March 31 - Earnings SummaryPulmonx Corp LUNG.OQ reported a quarterly adjusted loss of 33 cents per share for the quarter ended March 31, higher than ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL8N41C3JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4082","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631881521","title":"Pulmonx backs FY26 revenue view $90M-$92M, consensus $90.87M","url":"https://stock-news.laohu8.com/highlight/detail?id=2631881521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631881521?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:30","pubTimestamp":1777494626,"startTime":"0","endTime":"0","summary":"The company said, “Pulmonx (LUNG) continues to expect revenue for the full year 2026 to be in the range of $90 million to $92 million. The Company ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pulmonx-backs-fy26-revenue-view-90m-92m-consensus-90-87m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pulmonx-backs-fy26-revenue-view-90m-92m-consensus-90-87m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LUNG","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631267195","title":"Pulmonx Q1 revenue falls, slightly beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2631267195","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631267195?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:22","pubTimestamp":1777494176,"startTime":"0","endTime":"0","summary":"Pulmonx Q1 revenue falls, slightly beats estimatesOverviewMinimally invasive lung device maker's Q1 revenue fell 9% yr/yr, slightly beating analyst expectationsCompany's international revenue dropped ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nL1N41C1K7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUNG","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631255205","title":"Pulmonx Q1 EPS $(0.33) Beats $(0.34) Estimate, Sales $20.586M Beat $20.432M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2631255205","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631255205?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:06","pubTimestamp":1777493189,"startTime":"0","endTime":"0","summary":"Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.34) by 2.94 percent. This is a 8.33 percent increase over losses of $(0.36) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/04/52149815/pulmonx-q1-eps-0-33-beats-0-34-estimate-sales-20-586m-beat-20-432m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Pulmonx Q1 EPS $(0.33) Beats $(0.34) Estimate, Sales $20.586M Beat $20.432M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525690","title":"BRIEF-Pulmonx Q1 EPS USD -0.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525690","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525690?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493146,"startTime":"0","endTime":"0","summary":"BRIEF-Pulmonx Q1 EPS USD -0.33\n\n\nApr 29 (Reuters) - Pulmonx Q1 gross profit USD 16.044 million.\n\nQ1 revenue USD 20.586 million vs. IBES estimate USD 20.4 million\nQ1 income from operations USD -12.956 million\nQ1 pretax profit USD -13.505 million\nQ1 net income USD -13.654 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nPLXA025A3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525678","title":"Pulmonx Corp - Sees FY 2026 Cash, Cash Equivalents, and Securities to Decrease by $23 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525678","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525678?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493102,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nPLXA025A3:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631525514","title":"Pulmonx Outlook FY Gross Margin 75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631525514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631525514?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493102,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nPLXA025A3:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631252554","title":"Pulmonx Outlook FY Revenue USD 90-92 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2631252554","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631252554?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493102,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nPLXA025A3:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631552590","title":"Pulmonx Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2631552590","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631552590?lang=en_us&edition=fundamental","pubTime":"2026-04-30 04:05","pubTimestamp":1777493100,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., April  29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the \"Company\"), a global leader in minimally invasive treatments for lung disease, today repo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/29/3284252/0/en/Pulmonx-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","BK4082","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630331221","title":"Pulmonx Corp  expected to post a loss of 33 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2630331221","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630331221?lang=en_us&edition=fundamental","pubTime":"2026-04-28 04:04","pubTimestamp":1777320247,"startTime":"0","endTime":"0","summary":"Pulmonx Corp  expected to post a loss of33cents a share - Earnings Preview Pulmonx Corp LUNG.OQ LUNG.O is expected to  show a fall in quarterly revenue when it reports  results on April 29 for the per","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nL8N41A2B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237234","title":"Pulmonx to Report First Quarter 2026 Financial Results on April 29, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237234","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237234?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:05","pubTimestamp":1776283500,"startTime":"0","endTime":"0","summary":"REDWOOD CITY, Calif., April  15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it wil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/15/3274873/0/en/Pulmonx-to-Report-First-Quarter-2026-Financial-Results-on-April-29-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","LUNG","BK4198"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625641049","title":"Pulmonx Insiders Forfeit On 14% Gains After Selling Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2625641049","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625641049?lang=en_us&edition=fundamental","pubTime":"2026-04-05 20:02","pubTimestamp":1775390561,"startTime":"0","endTime":"0","summary":"Despite the fact that Pulmonx Corporation (NASDAQ:LUNG) stock rose 14% last week, insiders who sold US$371k worth of...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6022000-choice1-main-header/1585186795401"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lung/pulmonx/news/pulmonx-insiders-forfeit-on-14-gains-after-selling-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-lung/pulmonx/news/pulmonx-insiders-forfeit-on-14-gains-after-selling-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LUNG","BK4198","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618900895","title":"Pulmonx Faces Legal, Regulatory and Financial Risks From Off‑Label Use of Its Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2618900895","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618900895?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:02","pubTimestamp":1773295327,"startTime":"0","endTime":"0","summary":"Pulmonx Corporation (LUNG) has disclosed a new risk, in the Corporate Activity and Growth category. Pulmonx Corporation faces meaningful exposure i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmonx-faces-legal-regulatory-and-financial-risks-from-off‑label-use-of-its-products?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmonx-faces-legal-regulatory-and-financial-risks-from-off‑label-use-of-its-products?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4198","BK4082","LUNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617525349","title":"Pulmonx Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2617525349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617525349?lang=en_us&edition=fundamental","pubTime":"2026-03-05 22:28","pubTimestamp":1772720880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LUNG/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 05, 2026 09:28 ET (14:28 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4198","LUNG","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617054993","title":"Pulmonx Secures New Term Loan and Issues Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2617054993","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617054993?lang=en_us&edition=fundamental","pubTime":"2026-03-05 19:36","pubTimestamp":1772710561,"startTime":"0","endTime":"0","summary":"An update from Pulmonx ( ($LUNG) ) is now available. On March 2, 2026, Pulmonx Corporation entered into a new senior secured term loan facility of ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pulmonx-secures-new-term-loan-and-issues-warrants?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pulmonx-secures-new-term-loan-and-issues-warrants?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","LUNG","BK4198"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://pulmonx.com","stockEarnings":[{"period":"1week","weight":0.1716},{"period":"1month","weight":0.2362},{"period":"3month","weight":-0.0368},{"period":"6month","weight":-0.0368},{"period":"1year","weight":-0.4952},{"period":"ytd","weight":-0.2896}],"compareEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0513},{"period":"3month","weight":0.0829},{"period":"6month","weight":0.1043},{"period":"1year","weight":0.2961},{"period":"ytd","weight":0.1007}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.124032},{"month":2,"riseRate":0.666667,"avgChangeRate":0.086482},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.108699},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.069835},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.070668},{"month":6,"riseRate":0.4,"avgChangeRate":-0.087614},{"month":7,"riseRate":0.6,"avgChangeRate":-0.015052},{"month":8,"riseRate":0.6,"avgChangeRate":-0.034552},{"month":9,"riseRate":0.2,"avgChangeRate":-0.026077},{"month":10,"riseRate":0.4,"avgChangeRate":-0.055336},{"month":11,"riseRate":0.5,"avgChangeRate":-0.058171},{"month":12,"riseRate":0.833333,"avgChangeRate":0.20888}],"exchange":"NASDAQ","name":"Pulmonx Corp","nameEN":"Pulmonx Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pulmonx Corp(LUNG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pulmonx Corp(LUNG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pulmonx Corp,LUNG,Pulmonx Corp股票,Pulmonx Corp股票老虎,Pulmonx Corp股票老虎国际,Pulmonx Corp行情,Pulmonx Corp股票行情,Pulmonx Corp股价,Pulmonx Corp股市,Pulmonx Corp股票价格,Pulmonx Corp股票交易,Pulmonx Corp股票购买,Pulmonx Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pulmonx Corp(LUNG),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pulmonx Corp(LUNG) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}